[go: up one dir, main page]

AR033293A1 - Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos - Google Patents

Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos

Info

Publication number
AR033293A1
AR033293A1 ARP020101595A ARP020101595A AR033293A1 AR 033293 A1 AR033293 A1 AR 033293A1 AR P020101595 A ARP020101595 A AR P020101595A AR P020101595 A ARP020101595 A AR P020101595A AR 033293 A1 AR033293 A1 AR 033293A1
Authority
AR
Argentina
Prior art keywords
increase
biodisponibility
compositions
methods
pharmaceutical agents
Prior art date
Application number
ARP020101595A
Other languages
English (en)
Inventor
Elizabeth Everitt
Edward Han
Sajeev Cherian
Dale Kempf
Hing L Sham
Shi-Chung Ng
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR033293A1 publication Critical patent/AR033293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método para aumentar la biodisponibilidad de agentes farmacéuticamente activos. Se usa lopinavir, sus equivalentes aceptables para uso farmacéutico y derivados del mismo como inhibidores de la glicoproteína P.
ARP020101595A 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos AR033293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36735301P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
AR033293A1 true AR033293A1 (es) 2003-12-10

Family

ID=23446823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101595A AR033293A1 (es) 2001-05-01 2002-04-30 Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos

Country Status (10)

Country Link
US (1) US20020198160A1 (es)
EP (1) EP1387684A1 (es)
JP (1) JP2005511481A (es)
AR (1) AR033293A1 (es)
CA (1) CA2445967A1 (es)
MX (1) MXPA03010054A (es)
PE (1) PE20021075A1 (es)
TW (1) TWI231211B (es)
UY (1) UY27275A1 (es)
WO (1) WO2002087585A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0506498A (pt) * 2004-01-30 2007-02-13 Pfizer composições compreendendo inibidor de hiv protease e inibidor de atividade de enzima de citocromo p450
US7385084B2 (en) 2004-06-23 2008-06-10 Synta Pharmaceutical Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
JP2008536875A (ja) * 2005-04-15 2008-09-11 シンタ ファーマシューティカルズ コーポレーション ビス（チオヒドラジド）アミド化合物による併用癌療法
WO2007021881A1 (en) 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
AU2007288338B2 (en) 2006-08-21 2012-05-03 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US7939564B2 (en) * 2006-08-31 2011-05-10 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US7645904B2 (en) * 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
CA2669938C (en) * 2006-11-15 2016-01-05 Abbott Laboratories Solid pharmaceutical dosage formulations
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
NO2608792T3 (es) * 2010-08-26 2018-03-10
GB201808563D0 (en) 2018-05-24 2018-07-11 Univ Manchester Treatments
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments
GB201907305D0 (en) * 2019-05-23 2019-07-10 Douglas Pharmaceuticals Ltd Treatment of conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
TWI231211B (en) 2005-04-21
CA2445967A1 (en) 2002-11-07
US20020198160A1 (en) 2002-12-26
JP2005511481A (ja) 2005-04-28
WO2002087585A1 (en) 2002-11-07
MXPA03010054A (es) 2004-04-02
PE20021075A1 (es) 2002-12-07
EP1387684A1 (en) 2004-02-11
UY27275A1 (es) 2002-11-29

Similar Documents

Publication Publication Date Title
AR033293A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
SV2008001369A (es) Benzimidazoles
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
BR112016008016A2 (pt) inibidores de kras g12c
BRPI0513841A (pt) composto, composição farmacêutica, e uso do composto
EA200870545A1 (ru) Новые гетероциклические соединения
NI200900040A (es) Derivados de quinazolinona 5-substituidos como agentes antitumorales.
DK0991407T3 (da) Stabilisering af syresensitive benzimidazoler med amino/cyclodextrin-kombinationer
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
BR112015018087A8 (pt) composto, composição farmacêutica e uso
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
UY31430A1 (es) Derivados de piridina y pirazina -83
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
ECSP083351A (es) Composiciones farmacéuticas
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
UY27381A1 (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
AR031152A1 (es) Tratamientos nuevos para el sindrome de piernas inquietas
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
ECSP21060917A (es) Formulación de anticuerpos terapéuticos
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs

Legal Events

Date Code Title Description
FA Abandonment or withdrawal